Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $568.7M | $549M | $533.1M | $125.2M | $138.7M | |
| Gross Profit | $167.8M | $159.2M | $161.2M | $36.1M | $43M | |
| Operating Income | $46.1M | $35.3M | $42.8M | $6.9M | $13M | |
| EBITDA | $71.2M | $60.7M | $68.5M | $13.3M | $19.5M | |
| Diluted EPS | $1.45 | $0.88 | $1.12 | $0.13 | $0.39 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $157.5M | $227.2M | $244.8M | $250.9M | $258.1M | |
| Total Assets | $363.6M | $572.5M | $596.6M | $596.4M | $585.1M | |
| Current Liabilities | $62.4M | $88.1M | $94.7M | $61.2M | $73M | |
| Total Liabilities | $201.2M | $371.4M | $354.5M | $323.6M | $290.9M | |
| Total Equity | $162.4M | $201.1M | $242.1M | $272.9M | $294.2M | |
| Total Debt | $122.4M | $249.6M | $245.1M | $251.2M | $208.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $38.6M | $47.4M | $55.5M | $12.1M | $4.7M | |
| Cash From Investing | -$23.2M | -$35.9M | -$7.9M | -$1.6M | -$1.9M | |
| Cash From Financing | -$11.9M | $868K | -$45.5M | -$5.6M | -$12.7M | |
| Free Cash Flow | $25.8M | $36.7M | $47.6M | $10.5M | $2.8M | |
Allient, Inc. is a global engineering and manufacturing enterprise that develops solutions to drive the future of market-moving industries, including medical, life sciences, aerospace and defense, industrial automation, robotics, semi-conductor, transportation, agriculture, construction and facility infrastructure. The company was founded in 1962 and is headquartered in Amherst, NY.
In the current month, ALNT has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ALNT average analyst price target in the past 3 months is $52.75.
According to analysts, the consensus estimate is that Allient, Inc. share price will drop to $52.75 per share over the next 12 months.
Analysts are divided on their view about Allient, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Allient, Inc. is a Sell and believe this share price will rise from its current level to $35.00.
The price target for Allient, Inc. over the next 1-year time period is forecast to be $52.75 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
According to Wall Street analysts, the consensus rating for Allient, Inc. is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
You can purchase shares of Allient, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Allient, Inc. shares.
Allient, Inc. was last trading at $56.32 per share. This represents the most recent stock quote for Allient, Inc.. Yesterday, Allient, Inc. closed at $56.42 per share.
In order to purchase Allient, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.